| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period: 0% 0
Total Analysts: 2
Buy Ratings: 2 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 35.00 Median: 35.00 Highest: 35.00
- All
- Buy
- Hold
- Sell
- Yearly
- Quarterly
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -2.12 | -2.92 | -3.42 | -4.90 | -6.65 |
| P/E Ratio | -9.54 | -6.94 | -5.92 | -4.13 | -3.04 |
| EBIT | -79 | -122 | -164 | -238 | -325 |
| EBITDA | -77 | -125 | -176 | - | - |
| Net Profit | -78 | -115 | -156 | -238 | -325 |
| Net Profit Adjusted | - | - | - | - | - |
| Pre-Tax Profit | -78 | -115 | -156 | -238 | -325 |
| Net Profit (Adjusted) | -74 | -105 | -130 | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | -2.56 | -2.84 | -3.45 | -4.91 | -6.65 |
| Gross Income | - | - | - | - | - |
| Cash Flow from Investing | 224 | 185 | 218 | - | - |
| Cash Flow from Operations | -68 | -103 | -120 | - | - |
| Cash Flow from Financing | 224 | 185 | 218 | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | -243 | -236 | -347 | -379 | -145 |
| Research & Development Exp. | 56 | 96 | 131 | 190 | 230 |
| Capital Expenditure | 2 | 1 | 1 | - | - |
| Selling, General & Admin. Exp. | 21 | 25 | 29 | 48 | 95 |
| Shareholder’s Equity | 312 | 384 | 482 | - | - |
| Total Assets | 322 | 395 | 493 | - | - |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 4 | 4 | 4 | 4 | 4 |
| Average Estimate | -0.600 USD | -0.490 USD | -0.540 USD | -2.123 USD | -2.918 USD |
| Year Ago | - | - | - | -0.983 USD | - |
| Publish Date | - | - | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 3 | 3 | 3 | 4 | 4 |
| Average Estimate | 0 USD | 0 USD | 0 USD | 0 USD | 0 USD |
| Year Ago | - | - | - | 0 USD | - |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Rapport Therapeutics Inc Registered Shs | - | - | USD |
| 2022 | Rapport Therapeutics Inc Registered Shs | - | - | USD |
*Yield of the Respective Date
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
| Owner | in % |
|---|---|
| Freefloat | 53.07 |
| Third Rock Ventures LLC | 23.62 |
| Fidelity Management & Research Co. LLC | 14.52 |
| ARCH Venture Partners LLC | 10.87 |
| Cormorant Asset Management LP | 8.57 |
| American Funds Small Cap World Fund | 7.58 |
| Fidelity Growth Company Fund | 4.00 |
| Goldman Sachs & Co. LLC (Private Banking) | 3.74 |
| Abraham N. Ceesay, MBA | 2.30 |
| T Rowe Price Health Sciences Fund | 1.79 |
| Fidelity Growth Company K6 Fund | 1.40 |
| David Bredt, MD, PhD | 1.39 |
| Steven Marc Paul, MD | 1.39 |
| Fidelity Series Growth Company Fund | 1.03 |
| Swamy Yeleswaram, PhD | 0.85 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcL7Aqadmq6SksKw%3D